Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(19):1599; doi:10.1093/jnci/91.19.1599
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 19, 1599, October 6, 1999
© 1999 Oxford University Press

IN THIS ISSUE

Breast Cancer, Tamoxifen, and Endometrial Cancer

Tamoxifen is used both to treat breast cancer and to reduce breast cancer incidence among high-risk women. Tamoxifen has estrogen-like effects in the uterus and is associated with increased risk of endometrial cancer. Bernstein et al. (p. 1654) examined whether other known risk factors for endometrial cancer would alter the tamoxifen-endometrial cancer relationship. They found that tamoxifen-associated risk increases with prior use of estrogen replacement therapy. Women who are both obese and have a history of estrogen replacement therapy have an even more pronounced . . . [Full Text of this Article]

Screening in the Elderly

Lung Resistance-Related Protein and Multidrug Resistance

Prostate-Specific Antigen and Proliferation of Prostatic Stromal Cells

Mutations and Cervical Cancer

Matrix Metalloproteinase Inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?